C WorldWide Group Holding A S Trims Holdings in BioMarin Pharmaceutical Inc. (BMRN)

C WorldWide Group Holding A S lowered its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 14.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,972 shares of the biotechnology company’s stock after selling 14,809 shares during the quarter. C WorldWide Group Holding A S owned approximately 0.05% of BioMarin Pharmaceutical worth $8,281,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BMRN. Vanguard Group Inc. increased its holdings in shares of BioMarin Pharmaceutical by 4.7% in the second quarter. Vanguard Group Inc. now owns 14,345,027 shares of the biotechnology company’s stock valued at $1,302,816,000 after purchasing an additional 642,623 shares during the period. Jennison Associates LLC increased its holdings in shares of BioMarin Pharmaceutical by 33.8% in the second quarter. Jennison Associates LLC now owns 13,242,773 shares of the biotechnology company’s stock valued at $1,202,709,000 after purchasing an additional 3,348,168 shares during the period. TIAA CREF Investment Management LLC increased its holdings in shares of BioMarin Pharmaceutical by 63.7% in the second quarter. TIAA CREF Investment Management LLC now owns 2,251,011 shares of the biotechnology company’s stock valued at $204,437,000 after purchasing an additional 875,686 shares during the period. Manning & Napier Advisors LLC increased its holdings in shares of BioMarin Pharmaceutical by 25.2% in the second quarter. Manning & Napier Advisors LLC now owns 2,118,486 shares of the biotechnology company’s stock valued at $192,399,000 after purchasing an additional 426,016 shares during the period. Finally, Pictet Asset Management Ltd. increased its holdings in shares of BioMarin Pharmaceutical by 17.0% in the third quarter. Pictet Asset Management Ltd. now owns 1,134,622 shares of the biotechnology company’s stock valued at $105,599,000 after purchasing an additional 164,788 shares during the period. Institutional investors own 97.39% of the company’s stock.

Shares of BioMarin Pharmaceutical Inc. (BMRN) traded down $0.37 during trading hours on Friday, hitting $82.03. The stock had a trading volume of 842,100 shares, compared to its average volume of 1,590,635. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical Inc. has a twelve month low of $79.50 and a twelve month high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The business had revenue of $334.18 million for the quarter, compared to the consensus estimate of $347.38 million. During the same period in the prior year, the business earned $0.02 earnings per share. The business’s revenue was up 19.4% on a year-over-year basis. equities analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.66 EPS for the current fiscal year.

A number of research analysts have recently issued reports on the company. J P Morgan Chase & Co set a $130.00 target price on BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Sunday, October 29th. BMO Capital Markets boosted their target price on BioMarin Pharmaceutical from $117.00 to $119.00 and gave the company an “outperform” rating in a report on Friday, October 27th. Stifel Nicolaus dropped their target price on BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, October 27th. SunTrust Banks, Inc. set a $115.00 target price on BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Thursday, October 19th. Finally, Leerink Swann reissued an “outperform” rating and issued a $142.00 target price (up previously from $136.00) on shares of BioMarin Pharmaceutical in a report on Thursday, October 19th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the stock. BioMarin Pharmaceutical has a consensus rating of “Hold” and an average target price of $111.55.

WARNING: This report was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/11/12/c-worldwide-group-holding-a-s-trims-holdings-in-biomarin-pharmaceutical-inc-bmrn.html.

In other news, EVP Jeffrey Robert Ajer sold 3,521 shares of the company’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $95.00, for a total value of $334,495.00. Following the sale, the executive vice president now directly owns 49,299 shares in the company, valued at $4,683,405. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Henry J. Fuchs sold 15,000 shares of the company’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $90.50, for a total value of $1,357,500.00. Following the completion of the sale, the insider now owns 141,422 shares in the company, valued at $12,798,691. The disclosure for this sale can be found here. Insiders sold 40,686 shares of company stock worth $3,736,318 over the last 90 days. Company insiders own 1.85% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply